Treating COVID-19 - Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials during Pandemics

JAMA - Journal of the American Medical Association

Volumn 323, Issue 19, 2020, Pages 1897-1898

  Kalil, Andre C ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CHLOROQUINE; CORTICOSTEROID; FAVIPIRAVIR; HYDROXYCHLOROQUINE; INTERFERON; INTERLEUKIN 6 ANTIBODY; LOPINAVIR PLUS RITONAVIR; PLACEBO; REMDESIVIR; RIBAVIRIN; ANTIVIRUS AGENT;

ACUTE PANCREATITIS; ANAPHYLAXIS; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; CHINA; COMPASSIONATE USE; CONTROL GROUP; CORONAVIRUS DISEASE 2019; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; HEPATITIS; HUMAN; IN VITRO STUDY; INFECTION RISK; MEDICAL RESEARCH; MORTALITY RISK; NEUTROPENIA; NOTE; OFF LABEL DRUG USE; PANDEMIC; PLASMAPHERESIS; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH ETHICS; RISK BENEFIT ANALYSIS; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; TORSADE DES POINTES; UNITED STATES; BETACORONAVIRUS; CORONAVIRUS INFECTION; EBOLA HEMORRHAGIC FEVER; VIRUS PNEUMONIA;

ANTIVIRAL AGENTS; BETACORONAVIRUS; COMPASSIONATE USE TRIALS; CORONAVIRUS INFECTIONS; HEMORRHAGIC FEVER, EBOLA; HUMANS; OFF-LABEL USE; PANDEMICS; PNEUMONIA, VIRAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85082537970     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2020.4742     Document Type: Note

References (10)

1. Burton TM. Disputes emerge on African Ebola drug trials. Wall Street Journal. Published May 13, 2015. Accessed March 21, 2020. https://www.wsj.com/articles/disputes-emerge-on-african-ebola-drug-trials-1431471041
2. Davey RT Jr, Dodd L, Proschan MA,; PREVAIL II Writing Group; Multi-National PREVAIL II Study Team. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med. 2016; 375 (15): 1448-1456. doi: 10.1056/NEJMoa1604330 27732819
3. Adaptive COVID-19 Treatment Trial. ClinicalTrials.gov identifier: NCT04280705. Posted February 21, 2020. Accessed March 19, 2020. https://clinicaltrials.gov/ct2/show/NCT04280705?term=remdesivir&cond=covid-19&draw=2&rank=5
4. Young BE, Ong SWX, Kalimuddin S,; Singapore 2019 Novel Coronavirus Outbreak Research Team. Epidemiologic features and clinical course of patients infected With SARS-CoV-2 in Singapore. JAMA. Published online March 3, 2020. doi: 10.1001/jama.2020.3204 32125362
5. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. Published online February 24, 2020. doi: 10.1001/jama.2020.2648 32091533
6. Arabi YM, Mandourah Y, Al-Hameed F,; Saudi Critical Care Trial Group. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med. 2018; 197 (6): 757-767. doi: 10.1164/rccm.201706-1172OC 29161116
7. Lee N, Allen Chan KC, Hui DS, Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients. J Clin Virol. 2004; 31 (4): 304-309. doi: 10.1016/j.jcv.2004.07.006 15494274
8. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020; 395 (10223): 473-475. doi: 10.1016/S0140-6736(20)30317-2 32043983
9. Kalil AC, Sun J. Low-dose steroids for septic shock and severe sepsis: the use of Bayesian statistics to resolve clinical trial controversies. Intensive Care Med. 2011; 37 (3): 420-429. doi: 10.1007/s00134-010-2121-0 21243334
10. Actemra (tocilizumab). Prescribing information. Genentech; 2019. Accessed March 22, 2020. https://www.actemrahcp.com/?-ga=2.137041460.509331555.1584929819-505112783.1584929819